Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study
Table 4
Comparison of genotypic and allelic frequencies of polymorphisms rs10766197 of CYP2R1 gene and rs10877012 of CYP2B1 gene, between multiple sclerosis patients and control group.
Multiple sclerosis
Control group
OR
95% CI
rs10766197, CYP2R1 gene
Genotypes
GG (%)
43 (37.1)
112 (49.6)
—
—
GA (%)
58 (50.0)
90 (39.8)
—
—
0.08
AA (%)
15 (12.9)
24 (10.6)
—
—
versus GG (as referent)
73 (62.9)
114 (50.4)
1.67
1.05-2.64
0.03
versus AA (as referent)
101 (87.0)
202 (89.4)
0.8
0.40-1.59
0.59
Alleles 2n =684
2n =232
2n =452
A allele, 2n =226 (%)
88 (37.9)
138 (30.5)
1.39
0.99-1.94
0.05
G allele, (%)
144 (62.1)
314 (69.5)
0.72
0.52-1.00
0.05
rs10877012, CYP2B1 gene
Genotypes
GG (%)
55 (47.4)
101 (44.7)
—
—
GT (%)
48 (41.4)
98 (43.4)
—
—
0.90
TT (%)
13 (11.2)
27 (11.9)
—
—
versus GG (as referent)
61 (52.6)
125 (55.3)
0.89
0.57-1.40
0.63
versus TT (as referent)
103 (88.8)
199 (88.1)
1.08
0.53-2.17
0.84
Allele
G allele, (%)
158 (68.1)
300 (66.4)
1.08
0.77-1.52
0.65
T allele, (%)
74 (31.9)
152 (33.6)
0.92
0.66-1.30
0.65
For rs10766197 of CYP2R1 gene: GG: wild homozygous; GA: heterozygous; AA: polymorphic homozygous; for rs10877012 of CYP2B1 gene: GG: wild homozygous; GT: heterozygous; TT: polymorphic homozygous. OR: odds ratio risk; 95% CI: 95% confidence interval. values were obtained comparing multiple sclerosis versus control group.
